Literature DB >> 10427777

Severe bleeding following endoscopic variceal ligation: should EVL be avoided in Child C patients?

H Van Vlierberghe1, M De Vos, M Hautekeete, A Elewaut.   

Abstract

In the last decade there has been an evolution in the treatment of bleeding oesophageal varices. Endoscopic variceal ligation (EVL) is one of those new techniques that not only has shown to be more effective than sclerotherapy, but also causes less side effects, resulting in less episodes of rebleeding and improving survival. We describe severe bleeding in 3 patients after EVL, occurring between 5 and 10 days after the initial ligation. Two Child C patients could not be resuscitated and died shortly after this event. Severely impaired clotting function as a result of the liver disease and the greater size of the ulcers induced by EVL may contribute to this dramatic complication. Severe bleeding due to postligation ulceration may lead to death, which occurred in 2 of our Child C patients. Since more and more endoscopists are using EVL in the treatment of oesophageal variceal bleeding, they should be aware of the possible complications caused by this rather new technique.

Entities:  

Mesh:

Year:  1999        PMID: 10427777

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  3 in total

1.  Risk factors for predicting early variceal rebleeding after endoscopic variceal ligation.

Authors:  Liang Xu; Feng Ji; Qin-Wei Xu; Mie-Qing Zhang
Journal:  World J Gastroenterol       Date:  2011-07-28       Impact factor: 5.742

2.  Self-Expanding Metal Stent (SEMS): an innovative rescue therapy for refractory acute variceal bleeding.

Authors:  Kinesh Changela; Mel A Ona; Sury Anand; Sushil Duddempudi
Journal:  Endosc Int Open       Date:  2014-10-24

3.  Endoscopic variceal ligation-induced ulcer bleeding: What are the risk factors and treatment strategies?

Authors:  Eunae Cho; Chung Hwan Jun; Sung Bum Cho; Chang Hwan Park; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.